Related Experiment Video
Updated: Sep 17, 2025
04:34
Meta-Analysis of the Effectiveness and Safety of Shugan Jieyu Capsules for the Treatment of Insomnia
Published on: February 17, 2023
1.2K
One Single Session to Sleep Them All? The Potential of Single-Session Interventions for Insomnia
Matteo Carpi1, Erica Marie Szkody2, Daniel Ruivo Marques3,4
1Department of Human Neuroscience, Sapienza University of Rome, Rome, Italy.
Journal of Sleep Research
|June 30, 2025
Summary
Single-session interventions (SSIs) show promise for treating insomnia, a common mental health issue. Further research is needed to integrate these cost-effective, flexible approaches into stepped-care models for better accessibility.
Area of Science:
- Psychology
- Public Health
- Mental Health Treatment
Background:
- Insomnia is a widespread public health concern and a leading mental health disorder.
- It predicts depression and often co-occurs with other psychological issues.
- Current treatments like cognitive-behavioral therapy are effective but face accessibility barriers.
Purpose of the Study:
- To review the evidence for single-session interventions (SSIs) for insomnia.
- To explore the alignment between the SSI framework and insomnia treatment needs.
- To identify gaps in the integration of SSIs for insomnia.
Main Methods:
- Systematic review of existing literature on single-session interventions for insomnia.
- Analysis of the theoretical underpinnings and practical application of SSIs.
- Examination of clinical trial data for one-shot interventions based on cognitive-behavioral therapy for insomnia.
Main Results:
- SSIs are effective, flexible, and cost-effective for various mental health conditions.
- Several one-shot cognitive-behavioral therapy for insomnia interventions show promising results in trials.
- The integration of SSIs into a broader framework for insomnia treatment is currently limited.
Conclusions:
- The SSI framework aligns well with the needs of psychological insomnia treatments.
- Further research is required to develop and validate consensus-based SSIs for insomnia.
- Assessing the feasibility and effectiveness of SSIs within stepped-care models is crucial for improving accessibility.
Related Concept Videos
01:19Management of Insomnia
328
The sleep cycle, an integral part of human health, consists of several stages with distinct characteristics and functions. It begins with a transition from wakefulness to sleep, known as the light sleep phase, followed by the restorative deep sleep phase, essential for physical recovery and growth. The cycle concludes with the Rapid Eye Movement (REM) phase, characterized by high brain activity and vivid dreaming. Insomnia, a prevalent sleep disorder, involves difficulty falling asleep, staying...
328
01:27Insomnia
132
Insomnia is a prevalent sleep disorder characterized by difficulty falling asleep, frequent awakenings during the night, and waking up too early without being able to return to sleep. People with insomnia often experience these disruptions at least three nights a week for at least one month. Chronic insomnia, which lasts for at least three months, can lead to increased anxiety, which in turn can worsen sleep difficulties, creating a cycle of sleeplessness and stress.
Multiple factors contribute...
Multiple factors contribute...
132
01:17Sedatives and Hypnotics Drugs: Miscellaneous Agents
247
Sedatives and hypnotics encompass a wide range of substances, each with its unique mechanism of action, uses, and potential adverse effects.
Melatonin congeners like ramelteon (Rozerem) and tasimelteon (Hetlioz) selectively bind to melatonin receptors (MT1 and MT2) and thus mimic the actions of melatonin, a hormone that regulates sleep-wake cycles. Tasimelteon is primarily used for non-24-hour sleep-wake disorder, common in blind patients. They are also used to treat conditions like insomnia...
Melatonin congeners like ramelteon (Rozerem) and tasimelteon (Hetlioz) selectively bind to melatonin receptors (MT1 and MT2) and thus mimic the actions of melatonin, a hormone that regulates sleep-wake cycles. Tasimelteon is primarily used for non-24-hour sleep-wake disorder, common in blind patients. They are also used to treat conditions like insomnia...
247
02:07Blind Procedures
12.2K
Ideally, the people who observe and record the children’s behavior are unaware of who was assigned to the experimental or control group, in order to control for experimenter bias. Experimenter bias refers to the possibility that a researcher’s expectations might skew the results of the study. Remember, conducting an experiment requires a lot of planning, and the people involved in the research project have a vested interest in supporting their hypotheses. If the observers knew which...
12.2K
01:23Sedatives and Hypnotics: Overview
679
Sedatives are drugs that alleviate anxiety, while hypnotics induce sleep. Both classes of medication suppress neuronal activity, leading to a calming effect for sedatives and facilitating sleep for hypnotics.
Sedative-hypnotics are categorized into barbiturates, benzodiazepines (BZDs), and non-benzodiazepines or Z-drugs. These drugs work by suppressing central nervous system activity, and this suppression is dose-dependent. Older sedative medications, like barbiturates, follow a linear curve in...
Sedative-hypnotics are categorized into barbiturates, benzodiazepines (BZDs), and non-benzodiazepines or Z-drugs. These drugs work by suppressing central nervous system activity, and this suppression is dose-dependent. Older sedative medications, like barbiturates, follow a linear curve in...
679
01:14CNS Depressants: Barbiturates and Benzodiazepines
480
CNS depressants include drugs from the category of barbiturates and benzodiazepines. They are valuable medications for managing anxiety disorders and insomnia. Barbiturates, once used to induce and maintain sleep, have been replaced mainly by benzodiazepines due to barbiturate's toxicity, tolerance, and overdose risks. They interact with GABAA receptors, leading to sedation at low doses and potentially coma and death at higher doses. Phenobarbital, a long-acting barbiturate, possesses...
480